Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

PHASE3TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 3, 2016

Primary Completion Date

October 23, 2017

Study Completion Date

October 23, 2017

Conditions
Myelofibrosis With High Molecular Risk Mutations
Interventions
DRUG

Ruxolitinib

5 mg tablet for oral use

DRUG

Ruxolitinib Placebo

5 mg placebo tablet for oral use

Trial Locations (110)

2060

Novartis Investigative Site, Antwerp

2139

Novartis Investigative Site, Concord NSW

2170

Novartis Investigative Site, Liverpool

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Liège

4031

Novartis Investigative Site, Basel

4032

Novartis Investigative Site, Debrecen

4102

Novartis Investigative Site, Wooloongabba

5020

Novartis Investigative Site, Salzburg

6009

Novartis Investigative Site, Nedlands

7400

Novartis Investigative Site, Kaposvár

8091

Novartis Investigative Site, Zurich

9001

Novartis Investigative Site, Sankt Gallen

10002

Novartis Investigative Site, Taipei

10043

Novartis Investigative Site, Orbassano

11009

Novartis Investigative Site, Cadiz

18057

Novartis Investigative Site, Rostock

20122

Novartis Investigative Site, Milan

21100

Novartis Investigative Site, Varese

23563

Novartis Investigative Site, Lübeck

25123

Novartis Investigative Site, Brescia

27100

Novartis Investigative Site, Pavia

28041

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

29200

Novartis Investigative Site, Brest

33305

Novartis Investigative Site, Taoyuan District

34890

Novartis Investigative Site, Istanbul

38039

Novartis Investigative Site, Talas / Kayseri

38043

Novartis Investigative Site, Grenoble

40138

Novartis Investigative Site, Bologna

42123

Novartis Investigative Site, Reggio Emilia

44787

Novartis Investigative Site, Bochum

45147

Novartis Investigative Site, Essen

48527

Novartis Investigative Site, Nordhorn

49033

Novartis Investigative Site, Angers

50134

Novartis Investigative Site, Florence

50671

Novartis Investigative Site, Cologne

52074

Novartis Investigative Site, Aachen

53105

Novartis Investigative Site, Bonn

54511

Novartis Investigative Site, Vandœuvre-lès-Nancy

55139

Novartis Investigative Site, Samsun

59037

Novartis Investigative Site, Lille

61363

Novartis Investigative Site, Putzu City

64109

Novartis Investigative Site, Bayonne

70124

Novartis Investigative Site, Bari

70300

Novartis Investigative Site, Zrifin

73011

Novartis Investigative Site, Chambéry

74072

Novartis Investigative Site, Heilbronn

76038

Novartis Investigative Site, Rouen

81241

Novartis Investigative Site, München

83301

Novartis Investigative Site, Kaohsiung City

89081

Novartis Investigative Site, Ulm

91120

Novartis Investigative Site, Jerusalem

95123

Novartis Investigative Site, Catania

119228

Novartis Investigative Site, Singapore

129110

Novartis Investigative Site, Moscow

169608

Novartis Investigative Site, Singapore

191024

Novartis Investigative Site, Saint Petersburg

194044

Novartis Investigative Site, Saint Petersburg

1834111

Novartis Investigative Site, Afula

3525408

Novartis Investigative Site, Haifa

6423906

Novartis Investigative Site, Tel Aviv

A-1090

Novartis Investigative Site, Vienna

05403 000

Novartis Investigative Site, São Paulo

08270-070

Novartis Investigative Site, São Paulo

01236030

Novartis Investigative Site, São Paulo

M5G 2M9

Novartis Investigative Site, Toronto

DK 9000

Novartis Investigative Site, Aalborg

DK 2730

Novartis Investigative Site, Herlev

06202

Novartis Investigative Site, Nice

09113

Novartis Investigative Site, Chemnitz

01307

Novartis Investigative Site, Dresden

06120

Novartis Investigative Site, Halle S

04103

Novartis Investigative Site, Leipzig

115 27

Novartis Investigative Site, Athens

Novartis Investigative Site, Athens

570 10

Novartis Investigative Site, Thessaloniki

106 76

Novartis Investigative Site, Athens

265 00

Novartis Investigative Site, Pátrai

Unknown

Novartis Investigative Site, Hong Kong

H 1083

Novartis Investigative Site, Budapest

00168

Novartis Investigative Site, Rome

05100

Novartis Investigative Site, Terni

453-8511

Novartis Investigative Site, Nagoya

812-8582

Novartis Investigative Site, Fukuoka

371 8511

Novartis Investigative Site, Maebashi

650-0047

Novartis Investigative Site, Kobe

259-1193

Novartis Investigative Site, Isehara

565 0871

Novartis Investigative Site, Suita

113-8431

Novartis Investigative Site, Bunkyo Ku

160-0023

Novartis Investigative Site, Shinjuku-ku

409-3898

Novartis Investigative Site, Chūō

545-8586

Novartis Investigative Site, Osaka

N-5021

Novartis Investigative Site, Bergen

NO 1478

Novartis Investigative Site, Loerenskog

93-513

Novartis Investigative Site, Lodz

87 100

Novartis Investigative Site, Torun

50 367

Novartis Investigative Site, Wroclaw

8000-386

Novartis Investigative Site, Faro

4200-072

Novartis Investigative Site, Porto

SE-413 45

Novartis Investigative Site, Gothenburg

SE-14186

Novartis Investigative Site, Huddinge

SE-221 85

Novartis Investigative Site, Lund

451 80

Novartis Investigative Site, Uddevalla

06460

Novartis Investigative Site, Ankara

B15 2GW

Novartis Investigative Site, Edgbaston

BS10 5NB

Novartis Investigative Site, Westbruy on Trym

LS9 7TF

Novartis Investigative Site, Leeds

SE1 9RT

Novartis Investigative Site, London

M20 4BX

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY